Roche ends partnership with PDL over daclizumab for asthma

Roche ended its collaboration with PDL BioPharma over the development of experimental compound daclizumab in the treatment of asthma. However, an existing partnership between the companies to co-develop the drug in transplant maintenance will continue, PDL indicated Wednesday.

Roche decided to terminate the collaboration following a "portfolio review," PDL said in a statement. As a result, PDL now holds the exclusive rights to daclizumab for asthma and the company said it is "evaluating opportunities to establish a new collaboration" to continue the compound's development for this indication. The drug has shown "potential" in a Phase II trial for the treatment of asthma, PDL added.

Mid-stage studies of daclizumab for transplant maintenance are scheduled to begin next year, PDL stated, news sources report. Daclizumab is also being developed under a separate collaboration between PDL and Biogen Idec for multiple sclerosis, as well as for indications other than transplant and respiratory diseases.

To read more Top Story articles, click here.